Replies to post #3481 on China Growth Stocks

[BiotechValues]

SGTI Q4 earnings may be better than you expect Brennus.

CEO made comments in March:

"Industry developments are currently underway that we believe will positively impact our core business in addition to the momentum generated from the government healthcare reform initiatives. Specifically, a number of our key customers including Beijing Double-Crane Pharmaceutical Co., Ltd. and Kelun Pharmaceutical Co., Ltd., two of the largest domestic suppliers of medical transfusion solutions, have announced in recent months their plans to expand their production capacity in anticipation of capturing future growth opportunities. With the commencement of our new glucose production facility in October 2008, we have already effectively doubled our glucose production capability. We intend to leverage our expanded glucose production capability as well as our excellent customer relationships to further solidify our position as their supplier of choice for their basic pharmaceutical grade glucose."


http://www.shengtaipharmaceutical.com/cgi/search-en.cgi?f=news_en_1_+product_en+company_en_1_+contact_en&id=3984&t=news_en_1_